Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Philippe, Moris"'
Autor:
Heather Friberg, Morgan Gargulak, Amanda Kong, Leyi Lin, Luis J. Martinez, Alexander C. Schmidt, Robert M. Paris, Richard G. Jarman, Clemente Diaz, Stephen J. Thomas, Philippe Moris, Jeffrey R. Currier
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-10 (2022)
Abstract The increasing global impact of dengue underscores the need for a dengue virus (DENV) vaccine. We assessed B-cell and T-cell responses following vaccination with four formulations of a tetravalent dengue purified inactivated vaccine (DPIV) i
Externí odkaz:
https://doaj.org/article/2046e228a49043bda2bf6939924cdb61
Autor:
Isabel Leroux-Roels, Gwenn Waerlop, Jessika Tourneur, Fien De Boever, Catherine Maes, Jacques Bruhwyler, Delphine Guyon-Gellin, Philippe Moris, Judith Del Campo, Paul Willems, Geert Leroux-Roels, Alexandre Le Vert, Florence Nicolas
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
OVX836 is a recombinant protein-based vaccine targeting the highly conserved influenza nucleoprotein (NP), which aims to confer a broad-spectrum protection against influenza. In a Phase 1 study, OVX836, administered intramuscularly, has been found sa
Externí odkaz:
https://doaj.org/article/de7bec781d7f495881521c0c9f132984
Autor:
Philippe Moris, Kristen M. Bauer, Jeffrey R. Currier, Heather Friberg, Kenneth H. Eckels, Ines O. Esquilin, Robert V. Gibbons, Bruce L. Innis, Richard G. Jarman, Sriluck Simasathien, Peifang Sun, Stephen J. Thomas, Veerachai Watanaveeradej
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 9, Pp 2090-2105 (2019)
Three phase II randomized trials evaluated the safety/immunogenicity of two formulations of live-attenuated tetravalent dengue virus (TDEN) vaccine in dengue-endemic (Puerto Rico, Thailand) and non-endemic (US) regions (NCT00350337/NCT00370682/NCT004
Externí odkaz:
https://doaj.org/article/85423c0ddbfe4ec1a2141fd243dc8b6b
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 1, Pp 17-27 (2018)
The candidate malaria vaccine RTS,S has demonstrated 45.7% efficacy over 18 months against all clinical disease in a phase-III field study of African children. RTS,S targets the circumsporozoite protein (CSP), which is expressed on the Plasmodium spo
Externí odkaz:
https://doaj.org/article/3fc90a2aa03b40718470bb1421229873
Autor:
Javier Díez-Domingo, Xavier Sáez-Llorens, Miguel A Rodriguez-Weber, Cristina Epalza, Archana Chatterjee, Cheng-Hsun Chiu, Chien-Yu Lin, Andrea A Berry, Federico Martinón-Torres, Fernando Baquero-Artigao, Joanne M Langley, José T Ramos Amador, Joseph B Domachowske, Li-Min Huang, Nan-Chang Chiu, Susanna Esposito, Philippe Moris, Thi Lien-Anh Nguyen, Vanja Nikic, Wayne Woo, Yingjun Zhou, Ilse Dieussaert, Amanda Leach, Antonio Gonzalez Lopez, Nicolas Vanhoutte
Publikováno v:
The Journal of Infectious Diseases. 227:1293-1302
Background Safe and effective respiratory syncytial virus (RSV) vaccines remain elusive. This was a phase I/II trial (NCT02927873) of ChAd155-RSV, an investigational chimpanzee adenovirus-RSV vaccine expressing 3 proteins (fusion, nucleoprotein, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::768b31d656a9a507d8d2c90c9029980a
https://doi.org/10.1093/infdis/jiac481
https://doi.org/10.1093/infdis/jiac481
Autor:
Wivine Burny, Andrea Callegaro, Viviane Bechtold, Frédéric Clement, Sophie Delhaye, Laurence Fissette, Michel Janssens, Geert Leroux-Roels, Arnaud Marchant, Robert A. van den Berg, Nathalie Garçon, Robbert van der Most, Arnaud M. Didierlaurent, On Behalf of the ECR-002 Study Group, Isabelle Carletti, Arnaud Didierlaurent, Meral Esen, Julian Gabor, Edwige Haelterman, Caroline Hervé, Yves Horsmans, Peter Kremsner, Philippe Moris, Tino F Schwarz, Fernanda Tavares da Silva, Pascale Van Belle, Pierre Van Damme, Dirk Zuchner
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
To elucidate the role of innate responses in vaccine immunogenicity, we compared early responses to hepatitis B virus (HBV) surface antigen (HBsAg) combined with different Adjuvant Systems (AS) in healthy HBV-naïve adults, and included these paramet
Externí odkaz:
https://doaj.org/article/65af7ce2d89547bb915bf9bedc2e9b49
Autor:
Javier, Díez-Domingo, Xavier, Sáez-Llorens, Miguel A, Rodriguez-Weber, Cristina, Epalza, Archana, Chatterjee, Cheng-Hsun, Chiu, Chien-Yu, Lin, Andrea A, Berry, Federico, Martinón-Torres, Fernando, Baquero-Artigao, Joanne M, Langley, José T, Ramos Amador, Joseph B, Domachowske, Li-Min, Huang, Nan-Chang, Chiu, Susanna, Esposito, Philippe, Moris, Thi Lien-Anh, Nguyen, Vanja, Nikic, Wayne, Woo, Yingjun, Zhou, Ilse, Dieussaert, Amanda, Leach, Antonio, Gonzalez Lopez, Nicolas, Vanhoutte
Publikováno v:
The Journal of infectious diseases.
Safe and effective respiratory syncytial virus (RSV) vaccines remain elusive. This was a phase I/II trial (NCT02927873) of ChAd155-RSV, an investigational chimpanzee adenovirus-RSV vaccine expressing the F-, N- and M2-1 proteins, administered to 12-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8a91f1af52befae31c4370abc0fa93bd
https://pubmed.ncbi.nlm.nih.gov/36484484
https://pubmed.ncbi.nlm.nih.gov/36484484
Autor:
Philippe Moris, Richard G. Jarman, Edith Lepine, Leyi Lin, Rafael De La Barrera, Heather Friberg, Paul B. Keiser, Monica A. McArthur, Robert Paris, Kenneth H. Eckels, Alexander C. Schmidt, Michael Koren, David W. Vaughn, Stephen J. Thomas, Jeffrey R. Currier, Kirsten E. Lyke
Publikováno v:
The American Journal of Tropical Medicine and Hygiene
Dengue disease and its causative agents, the dengue viruses (DENV-1–4), cause high morbidity in tropical and subtropical regions. We evaluated three dosing regimens of the investigational tetravalent AS03B-adjuvanted dengue-purified inactivated vac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f1801a3e727660873b0bc343dd681d2
http://europepmc.org/articles/PMC7356407
http://europepmc.org/articles/PMC7356407
Autor:
Christian F Ockenhouse, Jason Regules, Donna Tosh, Jessica Cowden, April Kathcart, James Cummings, Kristopher Paolino, James Moon, Jack Komisar, Edwin Kamau, Thomas Oliver, Austin Chhoeu, Jitta Murphy, Kirsten Lyke, Matthew Laurens, Ashley Birkett, Cynthia Lee, Rich Weltzin, Ulrike Wille-Reece, Martha Sedegah, Jenny Hendriks, Isabella Versteege, Maria Grazia Pau, Jerold Sadoff, Yannick Vanloubbeeck, Marc Lievens, Dirk Heerwegh, Philippe Moris, Yolanda Guerra Mendoza, Erik Jongert, Joe Cohen, Gerald Voss, W Ripley Ballou, Johan Vekemans
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0131571 (2015)
In an observer blind, phase 2 trial, 55 adults were randomized to receive one dose of Ad35.CS.01 vaccine followed by two doses of RTS,S/AS01 (ARR-group) or three doses of RTS,S/AS01 (RRR-group) at months 0, 1, 2 followed by controlled human malaria i
Externí odkaz:
https://doaj.org/article/14f636e4d1aa427a8f17ce2775d30942
Autor:
Heather Friberg, Morgan Gargulak, Amanda Kong, Leyi Lin, Luis J. Martinez, Alexander C. Schmidt, Robert M. Paris, Richard G. Jarman, Clemente Diaz, Stephen J. Thomas, Philippe Moris, Jeffrey R. Currier
Publikováno v:
NPJ vaccines. 7(1)
The increasing global impact of dengue underscores the need for a dengue virus (DENV) vaccine. We assessed B-cell and T-cell responses following vaccination with four formulations of a tetravalent dengue purified inactivated vaccine (DPIV) in dengue-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63f63e3dca7b18c316807f701edf4bba
https://pubmed.ncbi.nlm.nih.gov/36316335
https://pubmed.ncbi.nlm.nih.gov/36316335